Asia
Innovate Biopharmaceuticals, Inc. and RDD Pharma, Ltd announced that the two companies entered into a definitive merger agreement pursuant to which Innovate agreed to acquire all of the outstanding capital stock of privately-held RDD in exchange for a combination of common and preferred shares.
MRI evaluation suggests slowing of cartilage damage and potential chondroprotection in osteoarthritis of the knee
Cerecin continues to strengthen its experienced team in Asia Pacific as it accelerates clinical development plans
BioSpace scanned the WARN (Worker Adjustment and Retraining Notification) notices across the country and compiled a small list of recent layoffs across the industry.
It was another busy week for clinical trials. Here’s a look.
Life science and pharma companies strengthen their leadership teams with this week’s appointments.
ASLAN Pharmaceuticals announced the presentation of new data from a phase 1b open-label, dose escalation study of varlitinib in combination with modified irinotecan and infusional 5-fluorouracil chemotherapy to determine the safety, tolerability and maximum tolerated dose in advanced solid tumours.
Companies from across the globe share information on their business and pipelines.
TLC announced the initiation of a Phase III clinical trial (“EXCELLENCE”) to evaluate the efficacy and safety of single as well as repeated doses of TLC599 in patients with osteoarthritis (OA) of the knee.
Eisai Co., Ltd. and Nichi-Iko Pharmaceutical have entered into a comprehensive collaboration agreement for the generic pharmaceutical business in China.
PRESS RELEASES